Immune responses to mucosal vaccination by the recombinant A1 and N proteins of infectious bronchitis virus.
Infectious bronchitis virus (IBV) is prevented primarily by the use of live attenuated vaccines, which are known to have a limited strain range of protection. Alternative vaccines against the emerging new virus strains can improve control of the disease. The aim of this study was to evaluate the immunogenic potential of two recombinant viral proteins, when administered by eyedrop, without the assistance of a vector. The recombinant S1 (rS1) and N (rN) proteins of the M41 strain expressed in E. coli were tested, and the live attenuated vaccine H120 was used as a positive control. Protection was evaluated by re-isolation of virus from tracheas of vaccinated chickens after challenge with strain M41. After three immunizations, rS1 glycoprotein induced 40% protection, while vaccination with rN provided no protection. Vaccination with rS1, rN, or H120 induced a cellular immune response as demonstrated by in vitro ChIFN-γ production by splenocytes of vaccinated birds. Vaccination with H120, and to a lesser extent rS1, induced HI and virus-specific IgG antibody production. These findings indicate that recombinant viral proteins administered through the mucosal route can evoke an immune response without the assistance of a vector.
Division of Avian and Aquatic Diseases, Kimron Veterinary Institute, Bet Dagan, Israel. rosiem@moag.gov.il
Rosie
R
Meir
Simi
S
Krispel
Lubov
L
Simanov
Dalia
D
Eliahu
Ora
O
Maharat
Jacob
J
Pitcovski
D058956:Administration, Mucosal; D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D002645:Chickens; D018352:Coronavirus Infections / Q000276:immunology / Q000517:prevention & control / Q000662:veterinary; D000086462:Coronavirus Nucleocapsid Proteins; D001351:Infectious bronchitis virus / Q000276:immunology* / Q000378:metabolism; D007371:Interferon-gamma / Q000096:biosynthesis; D008562:Membrane Glycoproteins / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology*; D019590:Nucleocapsid Proteins / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology*; D011201:Poultry Diseases / Q000276:immunology* / Q000517:prevention & control / Q000821:virology; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology*; D064370:Spike Glycoprotein, Coronavirus; D014611:Vaccination; D014759:Viral Envelope Proteins / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology*; D014765:Viral Vaccines / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology*
D000914:Antibodies, Viral; D000086462:Coronavirus Nucleocapsid Proteins; D008562:Membrane Glycoproteins; D019590:Nucleocapsid Proteins; D011994:Recombinant Proteins; D064370:Spike Glycoprotein, Coronavirus; D014759:Viral Envelope Proteins; D014765:Viral Vaccines; D007371:Interferon-gamma